Alternative to fishing – cell-based fish from the bioreactor – Nanowerk

Aug 02, 2021(Nanowerk News) 90 percent of all fish stocks are considered maximally exploited or overfished. As an alternative, cell-based fish, produced with the help of modern biotechnology, can make decisive contribution to secure the global supply of animal protein in the future.90 percent of all fish stocks are considered maximally exploited or overfished. As an alternative, cell-based fish, produced with the help of modern biotechnology, can make decisive contribution to secure the global supply of animal protein in the future.Cryosample of fish cells from the nitrogen tank.Bluu Biosciences is the first company in Europe to specialize in the development and production of cell-based fish.

Read more
Microphysiological Systems: Approaches, Applications and Opportunities – Technology Networks

Microphysiological systems (MPS), also commonly referred to as organ-on-a-chip or body-on-a-chip technologies, have gained considerable attention in recent years. They provide a more physiologically relevant setting compared to static two-dimensional cell culture assays or animal models, as they more closely recapitulate human physiology and the downstream effects of drugs on multiple tissues.

Read more
5 Health Benefits of Bitter Melon. #1 It Lowers Cholesterol – The Beet

Bitter melon is a fruit that you may never stumble across unless you find yourself in tropical areas or go out of your way to look for it in specialty markets, but it's certainly a good one to have on your radar right now, in light of the Delta variant cases rising across the country. Bitter melon is a plant native toSoutheast Asia, as well as the Amazon, East Africa, and the Caribbean, and has been used for centuries as a natural remedy for its medicinalproperties including treating symptoms of what we now know as modern-day diabetes. It's also known to help lower cholesterol and inflammation and may reduce your risk of certain cancers, but researchers point out thatmore studies are needed todetermine the mechanism for this to be proven

Read more
Putting patients at the heart of cell and gene therapy – PharmaLive

Nareda Mills Ben Beckley Putting patients at the heart of cell and gene therapy Authors: Nareda Mills, Global President Patient Solutions, EmerGENE Ben Beckley, Global Lead, EmerGENE About EmerGENE EmerGENE, is an end-to-end cell andgenetherapy network which promises to support small and midsize biotechs with the commercialization of their discoveries. The first of its kind,EmerGENEis a multidisciplinary team of Ashfield experts focused on delivering expert-led guidance to biotechs from clinical to commercial and beyond.Find out more: https://oneashfield.com/emergene-cell-gene-therapy Cell and gene therapies (C&GTs) present opportunities to not only treat disease, but to restore function and improve disease management

Read more
Korea to invest over W5tr in chips, bio, next-gen cars – The Korea Herald

South Korea plans invest over 5 trillion won ($4.3 billion) in semiconductors, biohealth and next-generation vehicles next year and provide them the latest tax benefits ahead of other industries, the nations fiscal policy chief said Thursday. The size of next years fiscal support for the industries dubbed the Big 3 will be larger than this years corresponding figure of some 4.2 trillion won.

Read more
CRISPR Therapeutics Provides Business Update and Reports – GlobeNewswire

- More than 45 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130 for the treatment of T-cell lymphoma- -Enrollment ongoing in CTX110, CTX120 and CTX130 clinical trials- ZUG, Switzerland and CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2021. We concluded an important quarter in which we reported notable data from our hemoglobinopathies program while rapidly advancing our entire clinical and pre-clinical portfolio and our capabilities, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics

Read more
Study Links Breastfeeding To Lower Blood Pressure In Early Childhood – Themississippilink

WASHINGTON A new study titled Breastfeeding in the First Days of Life Is Associated With Lower Blood Pressure at 3 Years of Age found that babies who were breastfed, even for a few days, had lower blood pressure as toddlers. These differences in blood pressure may translate into improved heart and vascular health in adults. The studys findings were published in theJournal of the American Heart Association, an open-access journal of theAmerican Heart Association.

Read more
Gene and Cell Therapies Expected to Offer New Treatment Paradigm in CNS Disorders; Market Expected to Increase at a CAGR of 45% During the Study…

LAS VEGAS, July 26, 2021 /PRNewswire/ -- DelveInsight's 'Gene and Cell Therapies Targeting CNS Disorders Market Insights and Market Forecast 2026' report offers a panoramic view of the current treatment practices, emerging cell and gene therapies to treat CNS disorders, market share of the individual therapies, current and forecasted Gene and Cell Therapies Targeting CNS Disorders market in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan) for the study period 20182026. Some of the focal points extracted from the Gene and Cell Therapies Targeting CNS Disorders Marketreport: Know more about the emerging therapy expected to penetrate the market significantly @ Gene and Cell Therapies Targeting CNS Disorders Market Insights, Pipeline Therapies, and Emerging Trends The report is created to project true opportunities in the Gene and Cell Therapies Targeting CNS Disorders market landscape, to help clients gain a competitive advantage over competitors, and to plan strategic moves to yield maximum ROI.

Read more